Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 79,305 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: Ketorolac; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: B Acute Lymphoblastic Leukemia
Interventions: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis; Drug · Procedure · Biological + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 39 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 455
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 279 more

Conditions: Pain, Postoperative, Pelvic Organ Prolapse
Interventions: Ice T, Motrin/Percocet/Dilaudid for breakthrough; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: PTSD
Interventions: Quetiapine, Placebo; Drug
Lead sponsor: Ralph H. Johnson VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Charleston, South Carolina

Conditions: Multiple Myeloma
Interventions: Nivolumab; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions: galinpepimut-S, pembrolizumab, Montanide, GM-CSF; Biological · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Santa Rosa, California • Whittier, California • Miami, Florida + 9 more

Conditions: Dry Eye Disease
Interventions: Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Budesonide / Formoterol, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acoustic Stimulation
Interventions: Acoustic Stimulation (STIM), No Acoustic Stimulation (SHAM), Daily acoustic stimulation (STIM2), No daily acoustic stimulation (SHAM2); Device
Lead sponsor: Michelle Stepan; Other
Eligibility: 18 Years to 25 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: LY2409021; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: AL Amyloidosis
Interventions: daratumumab; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neoplasms
Interventions: BI 907828, ezabenlimab, BI 754111; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: Santa Monica, California • New Haven, Connecticut • Athens, Georgia + 6 more

Conditions: End-Stage Renal Disease
Interventions: ESA Dose Adjustment per standard Anemia Management Protocol, ESA Dose Adjustment per "Smart Anemia Manager" Algorithm; Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Urinary Incontinence
Interventions: Implementation Strategy: Foundational Arm, Implementation Strategy: REACH Arm; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: TMJ, Osteoarthritis
Interventions: Plasma Rich in Growth Factor (PRGF) Supplementation, Triamcinolone Acetonide; Biological · Drug
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Trauma Exposure, Trauma, Trauma and Stressor Related Disorder, Mental Health Functioning, Chronic Medical Conditions, Chronic Medical Condition, Chronic Medical Illness, Posttraumatic Stress Disorder PTSD, Posttraumatic Stress Disorders, Posttraumatic Stress Symptoms, Posttraumatic Stress
Interventions: Structured Psychotherapy for Adolescents Responding to Chronic Stress - Group, Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents - Group, Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents - Individual, Structured Psychotherapy for Adolescents Responding to Chronic Stress - Individual; Behavioral
Lead sponsor: Anthony Vesco; Other
Eligibility: 8 Years to 18 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes
Interventions: exercise; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 30 Years to 75 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Sleep Disorder, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Brief Behavioral Therapy, Telephone-Based Intervention, Educational Intervention; Behavioral · Other
Lead sponsor: Gary Morrow; Other
Eligibility: 21 Years and older · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Stanford, California • Decatur, Illinois • Wichita, Kansas + 3 more

Conditions: Chronic Disease Prevention
Interventions: Technical assistance is designed to integrate Expert Recommendations for Implementing Change (ERIC) strategies, and Getting To Outcomes-TA.; Behavioral
Lead sponsor: Tennessee State University; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy Volunteers
Interventions: TAK-994 Oral Tablet, [14C]TAK-994 Intravenous Infusion, [14C]TAK-994 Oral Suspension; Drug
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Keloid
Interventions: Avotermin (Juvista), Placebo; Drug
Lead sponsor: Renovo; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Sclerosis, Healthy
Interventions: thoracic duct cannulation; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bacterial Pneumonia, Community-Acquired Infections
Interventions: Omadacycline, Moxifloxacin; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 774 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: Birmingham, Alabama • Mobile, Alabama • Laguna Hills, California + 9 more

Conditions: Migraine
Interventions: RELAXaHEAD Smartphone App Version 1, RELAXaHEAD Smartphone App Version 2; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 16 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Ice T Postoperative Multimodal Pain Regimen in FPMRS Surgery

Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo

Acoustic Stimulation, Sleep, and Cognitive-Emotional Processes in Young Adults With Anxiety and Depression Symptoms

A Study of LY2409021 Formulations in Healthy Participants

Daratumumab for the Treatment of Patients With AL Amyloidosis

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

Intelligent Control Approach to Anemia Management

Implementing a Mobile Health Application for Women Veterans With Urinary Incontinence (MyHealtheBladder): Function QUERI 3.0

Efficacy of PRGF Supplementation After TMJ Arthrocentesis in Patients With TMJ Osteoarthritis

Comparative Effectiveness of SPARCS and Unified Protocol for Youth With Chronic Medical Conditions and Trauma-Related Distress

Health Benefits of Aerobic and Resistance Training in Individuals With Type 2 Diabetes

Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

Engaging Partners in Caring Communities

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids

Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

RELAXaHEAD for Headache Patients (Phase III)